DrugBank ID: db00819
Synonymous :2-acetylamino-1,3,4-thiadiazole-5-sulfonamide | 5-acetamido-1,3,4-thiadiazole-2-sulfonamide | 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide | acetazolamid | acetazolamida | acétazolamide | acetazolamide | acetazolamidum | n-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide | n-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
Drug Sentece Context
Table 1. Analysis of context sentence of acetazolamide gene in 8 abstracts.
|32226695||In light of this, a countermeasure that has been shown to be effective in the analogous condition of HAPE is Acetazolamide. […] Acetazolamide has a myriad of effects on different organ systems, potently reduces hypoxic pulmonary vasoconstriction, improves minute ventilation and expired vital capacity. […] Acetazolamide, Nifedipine and Phosphodiesterase inhibitors may be potential countermeasures.|
|32330073||Drawing on this concept, it has also been proposed that treatments typically employed in the management of HAPE and other forms of acute altitude illness, pulmonary vasodilators and acetazolamide, should be considered for COVID-19. […] While of high utility in the management of HAPE and acute mountain sickness, systemically delivered pulmonary vasodilators and acetazolamide should not be used in the treatment of COVID-19, as they carry the risk of multiple adverse consequences including worsened ventilation-perfusion matching, impaired carbon dioxide transport, systemic hypotension and increased work of breathing.|
|32534175||The use of acetazolamide with or without sildenafil also needs to be explored with or without heparin, since increased oxygen delivery to vital organs through prevention of thrombosis/pulmonary emboli along with carbonic anhydrase inhibition may help increase oxygenation and prevent adverse clinical outcomes. […] Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; prevention with ivermectin as well as nutritional therapies that support a healthy immune response; treatment with anti-inflammatory therapies that block NF-κB and activate Nrf2 pathways, as well as novel therapies that address COVID-19 pneumonia and ARDS with DIC including anticoagulation and/or novel respiratory therapies with or without acetazolamide and sildenafil.|